Analysis of effectiveness of Fecal Microbiota Transplantation in Multiple Sclerosis
1 S.V.S Medical College, Yenugonda, Mahabubnagar, Telangana, India,5090012.
2 Odessa National Medical University, Valikhovskiy lane, 2, Odessa, Ukraine, 65000.
3 Andhra Medical College, Andhra Medical College, Maharanipeta, Visakhapatnam, India, 530003.
4 Rajasthan University of health sciences, sector 18, kumbha marg, pratap nagar, Jaipur, Rajasthan, India.
5 Azerbaijan Medical University, Samad Vurgun, Baku, Azerbaijan, AZ1022.
6 Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.
7 Chicago Hospitals and collaborative research institute, Chicago, Illinois, United States.
Review Article
World Journal of Advanced Research and Reviews, 2024, 23(02), 1285-1292
Article DOI: 10.30574/wjarr.2024.23.2.2483
Publication history:
Received on 06 July 2024; revised on 13 August 2024; accepted on 16 August 2024
Abstract:
Multiple Sclerosis is a chronic, autoimmune disorder characterized by demyelination and neuroinflammation affecting 2.3 million people around the world. MS have different types, relapsing and remitting MS being the most prevalent type with unpredicted flare ups with complete or incomplete recovery of the patient. Research suggests the emerging impact of alterations in gut microbiome on various diseases. The dysbiosis of gut flora has been linked to various diseases one of many is central nervous system autoimmune disorders.
The study aims to evaluate the potential role and effectiveness of FMT in treating MS.
The literature and clinical trials focused on gut microbiota, efficacy, Safety, and mechanisms of FMT were analyzed. The major focus of the study is assessing the impact of FMT on MS symptoms and gut microbiota composition and results of the study were concluded based on outcomes.
Primary outcomes noted improvement in MS symptoms both subjectively and objectively including enhanced motor symptoms and improved disability scores like EDSS. Secondary outcomes showed significant improvement in gut microbiota and 55-65% reduction in inflammatory markers like IL 6 and TNF alpha. FMT shows promising outcomes to be considered as a therapeutic intervention in MS by offering symptom relief and halting disease progression.
Keywords:
Multiple Sclerosis; Fecal microbiota transplantation; Gut brain axis; Neuroinflammation; Autoimmune disorder
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0